These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36515247)

  • 61. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
    Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial.
    Lee JM; Jung JH; Park KW; Shin ES; Oh SK; Bae JW; Rhew JY; Lee N; Kim DB; Kim U; Han JK; Lee SE; Yang HM; Kang HJ; Koo BK; Kim S; Cho YK; Shin WY; Lim YH; Rha SW; Kim SY; Lee SY; Kim YD; Chae IH; Cha KS; Kim HS
    Trials; 2015 Sep; 16():409. PubMed ID: 26374625
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis.
    Orban M; Kleeberger J; Ouarrak T; Freund A; Feistritzer HJ; Fuernau G; Geisler T; Huber K; Dudek D; Noc M; Montalescot G; Neumer A; Haller P; Clemmensen P; Zeymer U; Desch S; Massberg S; Schneider S; Thiele H; Hausleiter J
    Clin Res Cardiol; 2021 Sep; 110(9):1493-1503. PubMed ID: 33999281
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial.
    Vlachojannis GJ; Wilschut JM; Vogel RF; Lemmert ME; Delewi R; Diletti R; van der Waarden NWPL; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC
    Circulation; 2020 Dec; 142(24):2316-2328. PubMed ID: 33315489
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of Prasugrel and Ticagrelor for Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
    Fong LCW; Lee NHC; Yan AT; Ng MY
    Cardiology; 2022; 147(1):1-13. PubMed ID: 34743081
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Net clinical benefit of different strategies of dual antiplatelet therapy in elderly patients: Data from the praise registry.
    D'Ascenzo F; Elia E; de Filippo O; Manai R; Breviario S; Bruno F; Iannaccone M; Wańha W; Bianco M; Patti G; Raposeiras-Roubin S; Abu-Assi E; Bo M; De Ferrari GM; Conrotto F;
    Int J Cardiol; 2022 Apr; 353():9-14. PubMed ID: 35090983
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Usefulness of the PRECISE-DAPT score at differentiating between ticagrelor and prasugrel for dual antiplatelet therapy initiation.
    Ray A; Najmi A; Khandelwal G; Jhaj R; Sadasivam B
    J Thromb Thrombolysis; 2023 Oct; 56(3):411-413. PubMed ID: 37402078
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study.
    Jin C; Kim MH; Bang J; Serebruany V
    Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
    Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW
    Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial.
    Vranckx P; Valgimigli M; Odutayo A; Serruys PW; Hamm C; Steg PG; Heg D; Mc Fadden EP; Onuma Y; Benit E; Janssens L; Diletti R; Ferrario M; Huber K; Räber L; Windecker S; Jüni P;
    J Am Heart Assoc; 2021 Sep; 10(18):e015560. PubMed ID: 34533034
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Incidence and predictors of bleeding in ACS patients treated with PCI and prasugrel or ticagrelor: An analysis from the RENAMI registry.
    D'Ascenzo F; Grosso A; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Ali HH; Magnani G; Autelli M; Blanco PF; Garay A; Quadri G; Marra WG; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Raposeiras-Roubin S
    Int J Cardiol; 2018 Dec; 273():29-33. PubMed ID: 30228021
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
    Tomaniak M; Chichareon P; Onuma Y; Deliargyris EN; Takahashi K; Kogame N; Modolo R; Chang CC; Rademaker-Havinga T; Storey RF; Dangas GD; Bhatt DL; Angiolillo DJ; Hamm C; Valgimigli M; Windecker S; Steg PG; Vranckx P; Serruys PW;
    JAMA Cardiol; 2019 Nov; 4(11):1092-1101. PubMed ID: 31557763
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.
    Serruys PW; Takahashi K; Chichareon P; Kogame N; Tomaniak M; Modolo R; Chang CC; Komiyama H; Soliman O; Wykrzykowska JJ; de Winter RJ; Ferrario M; Dominici M; Buszman P; Bolognese L; Tumscitz C; Benit E; Stoll HP; Hamm C; Steg PG; Onuma Y; Jüni P; Windecker S; Vranckx P; Colombo A; Valgimigli M
    Eur Heart J; 2019 Aug; 40(31):2595-2604. PubMed ID: 31397487
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Incidence and pattern of urgent revascularization in acute coronary syndromes treated with ticagrelor or prasugrel.
    Aytekin A; Scalamogna M; Coughlan JJ; Lahu S; Ndrepepa G; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Witzenbichler B; Hochholzer W; Sibbing D; Angiolillo DJ; Hemetsberger R; Tölg R; Valina C; Müller A; Kufner S; Liebetrau C; Xhepa E; Hapfelmeier A; Sager HB; Joner M; Richardt G; Laugwitz KL; Neumann FJ; Schunkert H; Schüpke S; Kastrati A; Cassese S
    Clin Res Cardiol; 2024 Jul; 113(7):1060-1069. PubMed ID: 38740722
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial.
    Tomaniak M; Chichareon P; Klimczak-Tomaniak D; Takahashi K; Kogame N; Modolo R; Wang R; Ono M; Hara H; Gao C; Kawashima H; Rademaker-Havinga T; Garg S; Curzen N; Haude M; Kochman J; Gori T; Montalescot G; Angiolillo DJ; Capodanno D; Storey RF; Hamm C; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW; Anderson R
    Clin Res Cardiol; 2020 Jul; 109(7):930-943. PubMed ID: 31925529
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Features of antiplatelet therapy with P2Y12 receptor inhibitors in patients with myocardial infarction according to the Russian Register of Acute Myocardial Infarction REGION-MI.
    Boytsov SA; Shakhnovich RM; Tereschenko SN; Erlikh AD; Kukava NG; Pevsner DV; Rytova YK
    Kardiologiia; 2022 Sep; 62(9):44-53. PubMed ID: 36206137
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prognosis and the Effect of De-Escalation of Antiplatelet Therapy After Nuisance Bleeding in Patients With Myocardial Infarction.
    Choo EH; Choi IJ; Lim S; Moon D; Kim CJ; Park MW; Kim MC; Hwang BH; Lee KY; Seok Choi Y; Kim HY; Yoo KD; Jeon DS; Ahn Y; Chang K;
    Circ Cardiovasc Interv; 2022 Dec; 15(12):e012157. PubMed ID: 36382599
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prasugrel vs. ticagrelor after acute coronary syndrome: a critical appraisal of the ISAR-REACT 5 trial.
    Sulzgruber P; Niessner A
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):273-274. PubMed ID: 31865384
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.